<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02711176</url>
  </required_header>
  <id_info>
    <org_study_id>22/52/1662</org_study_id>
    <nct_id>NCT02711176</nct_id>
  </id_info>
  <brief_title>Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection</brief_title>
  <official_title>Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zahra Vahdat Shariatpanahi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ilam University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to investigate whether the efficacy of single-dose triple therapy
      (Esomeprazole 40 mg, Tinidazole 1 g, and Levofluxacine 500 mg) for 14 days is superior to
      double-dose lansoprazole 30 mg, amoxicillin 1 g and clarithromycin 500 mg for 14 days in the
      treatment of H pylori infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple regimens have been evaluated for H. pylori therapy in randomized controlled trials
      The treatment regimen that is selected must be effective, but considerations such as cost,
      side effects, and ease of administration should also be taken into account. Despite the
      number of studies, the optimal therapeutic regimen has not yet been defined.

      The regimen most commonly recommended for first line treatment of H. pylori is triple therapy
      with a PPI, amoxicillin and clarithromycin for 14 days. However, the multi-drug application
      is associated with remarkable side effects and it is not uncommon not to be able to complete
      a treatment course. Thus, treatment failure is associated with H. pylori strains that are
      resistant to the commonly used antibiotics. This study is conducted to investigate whether
      the efficacy of single-dose triple therapy (Esomeprazole 40 mg, Tinidazole 1 g, and
      Levofluxacine 500 mg) for 14 days is superior to double-dose lansoprazole 30 mg, amoxicillin
      1 g and clarithromycin 500 mg for 14 days in the treatment of H pylori infection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Actual">March 27, 2017</completion_date>
  <primary_completion_date type="Actual">March 27, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of H.pylori eradication</measure>
    <time_frame>42 days after study completion</time_frame>
    <description>Breath Urea Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Compliance</measure>
    <time_frame>within the first week after study completion</time_frame>
    <description>Interview</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Helicobacter Infection</condition>
  <arm_group>
    <arm_group_label>Tavanex &amp; Nexium &amp; Tinafas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Nexium (Esomeprazole) 40 mg daily and Tinafas (Tinidazole) 1 g daily and Tavanex (Levofloxacin) 500 mg daily for 14 days&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanzol &amp; Klacid &amp;Iramox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Lanzol (lansoprazole) 30 mg twice daily and Klacid (clarithromycin) 500 mg twice daily and Iramox (amoxicillin) 1 g twice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexium</intervention_name>
    <description>Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily</description>
    <arm_group_label>Tavanex &amp; Nexium &amp; Tinafas</arm_group_label>
    <other_name>Esomeprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinafas</intervention_name>
    <description>Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily</description>
    <arm_group_label>Tavanex &amp; Nexium &amp; Tinafas</arm_group_label>
    <other_name>Tinidazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tavanex</intervention_name>
    <description>Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily</description>
    <arm_group_label>Tavanex &amp; Nexium &amp; Tinafas</arm_group_label>
    <other_name>Levofluxacine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanzol</intervention_name>
    <description>Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily</description>
    <arm_group_label>Lanzol &amp; Klacid &amp;Iramox</arm_group_label>
    <other_name>lansoprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Klacid</intervention_name>
    <description>Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily</description>
    <arm_group_label>Lanzol &amp; Klacid &amp;Iramox</arm_group_label>
    <other_name>clarithromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iramox</intervention_name>
    <description>Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily</description>
    <arm_group_label>Lanzol &amp; Klacid &amp;Iramox</arm_group_label>
    <other_name>amoxicillin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients who proved H. pylori infection following three methods

               -  Positive rapid urease test

               -  Histologic evidence of H. pylori by modified Giemsa staining

               -  Positive stool Antigen Test

        Exclusion Criteria:

          -  Patients who received eradication therapy for H. pylori infection, previously

          -  H. pylori eradication failure because of poor compliance

          -  The administration of antibiotics or the consumption of bismuth salts within 4 weeks
             or the administration of a proton pump inhibitor (PPI) within 2 weeks

          -  Advanced gastric cancer or other malignancy

          -  Abnormal liver function or liver cirrhosis

          -  Abnormal renal function or chronic kidney disease

          -  Other severe concurrent diseases

          -  Previous allergic reactions to the study drugs

          -  Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaahin Shahbazi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor, Ilam University of Medical Sciences,Head of Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ilam University of Medical Scienvc</name>
      <address>
        <city>Ilam</city>
        <zip>6939177143</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>June 7, 2017</last_update_submitted>
  <last_update_submitted_qc>June 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ilam University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Vahdat Shariatpanahi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Tinidazole</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

